↓ Skip to main content

Dove Medical Press

Article Metrics

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, April 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
65 Mendeley
Title
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
Published in
International Journal of Chronic Obstructive Pulmonary Disease, April 2016
DOI 10.2147/copd.s54513
Pubmed ID
Authors

Jill Ohar, Joshua Cohen, Matthew C Miles, James Donohue

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and health care expenditure worldwide. Relaxation of airway smooth muscle with inhaled bronchodilators is the cornerstone of treatment for stable COPD, with inhaled corticosteroids reserved for those with a history of exacerbations. Tiotropium has occupied center stage in COPD treatment for over 10 years and improves lung function, quality of life, exercise endurance, and reduces the risk of COPD exacerbation. Long-acting β2-agonists (LABAs) improve lung function, reduce dynamic hyperinflation, increase exercise tolerance, health-related quality of life, and reduce acute exacerbation of COPD. The combination of long-acting muscarinic antagonists (LAMAs) and LABAs is thought to leverage different pathways to induce bronchodilation using submaximal drug doses, increasing the benefits and minimizing receptor-specific side effects. Umeclidinium/vilanterol is the first combination of LAMA/LABA to be approved for use in stable COPD in USA and Europe. Additionally, indacaterol/glycopyrronium and aclidinium/formoterol have been approved in Europe and in numerous locations outside USA. Several other agents are in the late stages of development, most of which offer once-daily dosing. The benefits of new LAMA/LABA combinations include improved pulmonary function, dyspnea, and health-related quality of life, and in some cases, reduced exacerbations. These evolving treatments will provide new opportunities and challenges in the management of COPD.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 65 100%

Demographic breakdown

Readers by professional status Count As %
Other 15 23%
Student > Ph. D. Student 9 14%
Student > Bachelor 8 12%
Researcher 6 9%
Student > Master 6 9%
Other 16 25%
Unknown 5 8%
Readers by discipline Count As %
Medicine and Dentistry 40 62%
Pharmacology, Toxicology and Pharmaceutical Science 6 9%
Biochemistry, Genetics and Molecular Biology 4 6%
Economics, Econometrics and Finance 2 3%
Mathematics 1 2%
Other 3 5%
Unknown 9 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2016.
All research outputs
#6,869,827
of 13,633,853 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#690
of 1,657 outputs
Outputs of similar age
#93,462
of 260,903 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#33
of 65 outputs
Altmetric has tracked 13,633,853 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,657 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,903 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.